Keywords
Last Name
Institution

Louis M. Aledort

TitlePROFESSOR
InstitutionMount Sinai
DepartmentHematology and Medical Oncology
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756
Fax212-987-3326

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia. 2014 Jan; 20(1):83-91.
      View in: PubMed
    2. Rangarajan S, Kessler C, Aledort L. The clinical implications of ADAMTS13 function: the perspectives of haemostaseologists. Thromb Res. 2013 Oct; 132(4):403-7.
      View in: PubMed
    3. Elliott BM, Aledort LM. Restoring hemostasis: fibrinogen concentrate versus cryoprecipitate. Expert Rev Hematol. 2013 Jun; 6(3):277-86.
      View in: PubMed
    4. Rangarajan S, Aledort L. Will gene therapy trump factor treatment in hemophilia? Expert Rev Hematol. 2013 Feb; 6(1):43-8.
      View in: PubMed
    5. Carcao M, Malkin D, Aledort L. Symposium on congenital and acquired bleeding disorders in children (in honor of the lifetime accomplishments of Dr. Victor S. Blanchette in pediatric hematology). Pediatr Blood Cancer. 2013; 60 Suppl 1:S1.
      View in: PubMed
    6. Pintova S, Bhardwaj AS, Aledort LM. IVIG--a hemolytic culprit. N Engl J Med. 2012 Sep 6; 367(10):974-6.
      View in: PubMed
    7. Kisker C, Aledort L, Farin H. Efficacy evaluation of products for treatment of bleeding episodes. Haemophilia. 2012 Sep; 18(5):e367-9.
      View in: PubMed
    8. Gringeri A, Lambert T, Street A, Aledort L. Tertiary prophylaxis in adults: is there a rationale? Haemophilia. 2012 Sep; 18(5):722-8.
      View in: PubMed
    9. Bander J, Elmariah S, Aledort LM, Dlott J, Stelzer P, Halperin JL, Kini AS, Sharma SK. Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty. Thromb Haemost. 2012 Jul; 108(1):86-93.
      View in: PubMed
    10. Frontera JA, Aledort L, Gordon E, Egorova N, Moyle H, Patel A, Bederson JB, Sehba F. Early platelet activation, inflammation and acute brain injury after a subarachnoid hemorrhage: a pilot study. J Thromb Haemost. 2012 Apr; 10(4):711-3.
      View in: PubMed
    11. Cromwell C, Aledort LM. FEIBA: a prohemostatic agent. Semin Thromb Hemost. 2012 Apr; 38(3):265-7.
      View in: PubMed
    12. Aledort L, Bullinger M, von Mackensen S, Wasserman J, Young NL, Globe D. Why should we care about quality of life in persons with haemophilia? Haemophilia. 2012 May; 18(3):e154-7.
      View in: PubMed
    13. Sheth S, Soff G, Mitchell B, Green D, Kaicker S, Fireman F, Tugal O, Guarini L, Giardina P, Aledort L. Managing incidentally diagnosed isolated factor VII deficiency perioperatively: a brief expert consensus report. Expert Rev Hematol. 2012 Feb; 5(1):47-50.
      View in: PubMed
    14. Fogarty PF, Olin JW, Kessler CM, Konkle BA, Aledort LM. An algorithmic approach to peripheral artery disease in hemophilia: extrapolation of management principles from noncoagulopathic patients. Blood Coagul Fibrinolysis. 2012 Jan; 23(1):23-9.
      View in: PubMed
    15. Lipshitz J, Chelliah T, Aledort L. A case of factor V inhibitor with complete correction of the PT and aPTT upon mixing. Am J Hematol. 2012 Mar; 87(3):313-5.
      View in: PubMed
    16. Aledort LM. Another role for the VW molecule. Haemophilia. 2012 Mar; 18(2):246-7.
      View in: PubMed
    17. Kurth M, Puetz J, Kouides P, Sanders J, Sexauer C, Bernstein J, Gruppo R, Manco-Johnson M, Neufeld EJ, Rodriguez N, Wicklund B, Quon D, Aledort L. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost. 2011 Nov; 9(11):2229-34.
      View in: PubMed
    18. Aledort LM, Navickis RJ, Wilkes MM. Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies. J Thromb Haemost. 2011 Nov; 9(11):2180-92.
      View in: PubMed
    19. Aledort LM, Navickis RJ, Wilkes MM. Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII. J Thromb Haemost. 2011 Nov; 9(11):2325-7.
      View in: PubMed
    20. Aledort LM. Treatment of factor XI deficiency. Clin Adv Hematol Oncol. 2011 Apr; 9(4):305-6.
      View in: PubMed
    21. Bar-Chama N, Snyder S, Aledort L. Sexual evaluation and treatment of ageing males with haemophilia. Haemophilia. 2011 Nov; 17(6):875-83.
      View in: PubMed
    22. Aledort LM. Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment. J Thromb Haemost. 2011 Mar; 9(3):423-7.
      View in: PubMed
    23. Kremyanskaya M, Aledort L. Acquired hemophilia: we now see it with myeloproliferative neoplasms. Am J Hematol. 2011 Mar; 86(3):329-30.
      View in: PubMed
    24. Misra D, Aledort L. Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy. Am J Hematol. 2011 Feb; 86(2):235.
      View in: PubMed
    25. Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011 Jan; 14(1):90-6.
      View in: PubMed
    26. Aledort LM. Off-label use of recombinant activated factor VII--safe or not safe? N Engl J Med. 2010 Nov 4; 363(19):1853-4.
      View in: PubMed
    27. Dembitzer FR, Suarez Y, Aledort LM, Peerschke EI. Screening coagulation testing using the APTT: which reagent to choose? Am J Hematol. 2010 Sep; 85(9):726.
      View in: PubMed
    28. Aledort LM. Optimizing the treatment of haemophilia B: laboratory and clinical perspectives. Haemophilia. 2010 Jul; 16 Suppl 6:1-2.
      View in: PubMed
    29. Stanca CM, Fiel MI, Aledort L, Cohen E, del Rio Martin J, Schiano TD. Factors associated with persistent thrombocytopenia after liver transplantation. Transplant Proc. 2010 Jun; 42(5):1769-73.
      View in: PubMed
    30. O'Connor DS, Elmariah S, Aledort LM, Pinney SP. Disseminated intravascular coagulation complicating Epstein-Barr virus infection in a cardiac transplant recipient: a case report. Transplant Proc. 2010 Jun; 42(5):1973-5.
      View in: PubMed
    31. Misra D, Bednar M, Cromwell C, Marcus S, Aledort L. Manifestations of superwarfarin ingestion: a plea to increase awareness. Am J Hematol. 2010 May; 85(5):391-2.
      View in: PubMed
    32. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost. 2010 Jun; 8(6):1372-82.
      View in: PubMed
    33. Aledort LM. To bleed or not to bleed - is that a question? J Thromb Haemost. 2010 Jan; 8(1):81-2.
      View in: PubMed
    34. Zakarija A, Aledort L. How we treat: venous thromboembolism prevention in haemophilia patients undergoing major orthopaedic surgery. Haemophilia. 2009 Nov; 15(6):1308-10.
      View in: PubMed
    35. Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia. 2009 Nov; 15(6):1197-209.
      View in: PubMed
    36. Aledort LM. Mild and moderate factor VIII deficiency: inhibitor risks. J Thromb Haemost. 2009 Jun; 7(6):928-9.
      View in: PubMed
    37. Olowokure O, Fishman M, Cromwell C, Aledort L. DDAVP for von Willebrand menorrhagia--severe hyponatraemia, haemolysis, seizure, coma.!! Caution. Haemophilia. 2009 May; 15(3):837.
      View in: PubMed
    38. Cromwell C, Tarantino M, Aledort LM. Safety of anti-D during pregnancy. Am J Hematol. 2009 Apr; 84(4):261-2.
      View in: PubMed
    39. Lee CA, Aledort LM. Bleeding and clotting: new therapies and old issues revisited. Haemophilia. 2009 Mar; 15(2):592-6.
      View in: PubMed
    40. Aledort LM. Expert Review of Hematology: addressing the needs of a broad research field. Expert Rev Hematol. 2008 Oct; 1(1):1-2.
      View in: PubMed
    41. Sealove BA, Aledort LM, Stacy CB, Halperin JL. Recurrent orthostatic global amnesia in a patient with postoperative hyperfibrinogenemia. J Stroke Cerebrovasc Dis. 2008 Jul-Aug; 17(4):241-3.
      View in: PubMed
    42. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2; 371(9610):395-403.
      View in: PubMed
    43. Rivard GE, Aledort L. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease. Haemophilia. 2008 Mar; 14(2):271-5.
      View in: PubMed
    44. Aledort LM. History of haemophilia. Haemophilia. 2007 Dec; 13 Suppl 5:1-2.
      View in: PubMed
    45. Lee CA, Aledort LM. Coagulation deficiencies: a look to the future. Haemophilia. 2007 Nov; 13(6):750-7.
      View in: PubMed
    46. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia. 2008 Jan; 14(1):39-43.
      View in: PubMed
    47. Altomare I, Adler A, Aledort LM. The 5, 10 methylenetetrahydrofolate reductase C677T mutation and risk of fetal loss: a case series and review of the literature. Thromb J. 2007; 5:17.
      View in: PubMed
    48. Feldman BM, Aledort L, Bullinger M, Delaney FM, Doria AS, Funk S, Giangrande P, Lundin B, Manco-Johnson M, Miners A, Scriba PC, Srivastava A, Schramm W, Blanchette VS. The economics of haemophilia prophylaxis: governmental and insurer perspectives. Proceedings of the Second International Prophylaxis Study Group (IPSG) symposium. Haemophilia. 2007 Nov; 13(6):745-9.
      View in: PubMed
    49. Tarantino M, Ma A, Aledort L. Safety of human plasma-derived clotting factor products and their role in haemostasis in patients with haemophilia: meeting report. Haemophilia. 2007 Sep; 13(5):663-9.
      View in: PubMed
    50. Kraut EH, Aledort LM, Arkin S, Stine KC, Wong WY. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia. 2007 Sep; 13(5):508-17.
      View in: PubMed
    51. Aledort LM, Salama A, Kovaleva L, Robak T, Newland AC, Nugent DJ, Brenner B, Zenker O. Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac) in chronic immune thrombocytopenic purpura. Hematology. 2007 Aug; 12(4):289-95.
      View in: PubMed
    52. Carcao MD, Aledort LM. Prophylaxis in the haemophilia population-optimizing therapy. Haemophilia. 2007 May; 13(3):227-32.
      View in: PubMed
    53. Goedert JJ, Chen BE, Preiss L, Aledort LM, Rosenberg PS. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990. Am J Epidemiol. 2007 Jun 15; 165(12):1443-53.
      View in: PubMed
    54. Aledort LM, Evatt BL, Lusher JM, Brownstein AP. HIV and hemophilia. J Thromb Haemost. 2007 Mar; 5(3):607-10.
      View in: PubMed
    55. Di Paola J, Aledort L, Britton H, Carcao M, Grabowski E, Hutter J, Journeycake J, Kempton C, Leissinger C. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia. 2006 Nov; 12(6):591-7.
      View in: PubMed
    56. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J, Wasser JS, Wiznitzer I, Kelly R, Chen CF, Nichol JL. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006 Oct 19; 355(16):1672-81.
      View in: PubMed
    57. Aledort LM. MedWatch: an important instrument for postlicensing surveillance. J Thromb Haemost. 2006 Jul; 4(7):1637.
      View in: PubMed
    58. Altomare I, Desman G, Aledort LM. Echinocytosis--an unusual manifestation of hemangioma. Am J Hematol. 2006 Jul; 81(7):532-4.
      View in: PubMed
    59. Aledort LM. Can we prevent inhibitors in mild and moderate factor VIII-deficient patients? J Thromb Haemost. 2006 Apr; 4(4):914.
      View in: PubMed
    60. Aledort L, Ljung R, Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost. 2006 Mar; 4(3):503-4.
      View in: PubMed
    61. Brown SA, Aledort LM, Lee CA. Current issues facing coagulationists--meeting report. Haemophilia. 2006 Mar; 12(2):115-23.
      View in: PubMed
    62. Allen G, Aledort L. Therapeutic decision-making in inhibitor patients. Am J Hematol. 2006 Jan; 81(1):71-2.
      View in: PubMed
    63. Sieger L, Aledort L. Inhibitor challenges in the paediatric setting. Haemophilia. 2006 Jan; 12(1):106-7.
      View in: PubMed
    64. Aledort LM, Goudemand J. United States' factor XI-deficiency patients need a safer treatment. Am J Hematol. 2005 Dec; 80(4):301-2.
      View in: PubMed
    65. Mathew P, Manno CS, Aledort LM. Therapeutic choices in the current millennium: hemophilia workshop highlights. Pediatr Blood Cancer. 2005 Oct 15; 45(5):611-5.
      View in: PubMed
    66. Aledort LM, Coates J. Can managed care support hemophilia in the 21st century? Am J Hematol. 2005 Jun; 79(2):172-3.
      View in: PubMed
    67. Mayer SA, Aledort LM. Thrombotic microangiopathy: differential diagnosis, pathophysiology and therapeutic strategies. Mt Sinai J Med. 2005 May; 72(3):166-75.
      View in: PubMed
    68. Sallah S, Aledort L. Treatment of patients with acquired inhibitors. J Thromb Haemost. 2005 Mar; 3(3):595-7.
      View in: PubMed
    69. Aledort LM. Platelet bleeding disorders and approach to their management. Curr Hematol Rep. 2005 Mar; 4(2):85-7.
      View in: PubMed
    70. Young G, Aledort L. Therapy for haemophilia: recent advances and goals for the future. Expert Opin Emerg Drugs. 2005 Feb; 10(1):173-84.
      View in: PubMed
    71. Brown SA, Aledort LM. Economic challenges in haemophilia. Haemophilia. 2005 Jan; 11(1):64-72.
      View in: PubMed
    72. Monahan PE, Aledort LM. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody. Am J Hematol. 2004 Dec; 77(4):346-50.
      View in: PubMed
    73. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004 Oct; 2(10):1700-8.
      View in: PubMed
    74. Aledort LM. Hemophilia replacement products, clinical trials: inhibitors and pharmacokinetics-can they be done? J Thromb Haemost. 2004 Oct; 2(10):1855-6.
      View in: PubMed
    75. Theodore D, Fried MW, Kleiner DE, Kroner BL, Goedert JJ, Eyster ME, Faust SP, Sherman KE, Kessler CM, Francis C, Aledort LM. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia. 2004 Sep; 10(5):413-21.
      View in: PubMed
    76. Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004 Jul; 76(3):205-13.
      View in: PubMed
    77. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev. 2004 Jun; 18(2):101-13.
      View in: PubMed
    78. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost. 2004 Jun; 2(6):861-2.
      View in: PubMed
    79. Tarantino MD, Aledort LM. Advances in clotting factor treatment for congenital hemorrhagic disorders. Clin Adv Hematol Oncol. 2004 Jun; 2(6):363-8.
      View in: PubMed
    80. Aledort LM. AIDS, hepatitis and hemophilia. J Thromb Haemost. 2004 Mar; 2(3):521.
      View in: PubMed
    81. Aledort LM. Do we need a better test? Can thrombin generation be useful? Curr Hematol Rep. 2004 Mar; 3(2):75-6.
      View in: PubMed
    82. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia. 2004 Jan; 10(1):63-8.
      View in: PubMed
    83. Aledort LM. Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe? J Thorac Cardiovasc Surg. 2003 Dec; 126(6):2112-3.
      View in: PubMed
    84. Brown SA, Aledort LM, Lee CA. Molecular challenges and viral diseases. Haemophilia. 2003 Nov; 9(6):727-37.
      View in: PubMed
    85. Aledort LM. Choice of replacement therapy for hemophilia. J Thromb Haemost. 2003 Mar; 1(3):596.
      View in: PubMed
    86. Aledort LM. Orthopedic outcome studies and cost issues. Semin Thromb Hemost. 2003 Feb; 29(1):55-60.
      View in: PubMed
    87. Aledort LM. Why thrombin generation? From bench to bedside. Pathophysiol Haemost Thromb. 2003; 33(1):2-3.
      View in: PubMed
    88. Brown SA, Aledort LM, Astermark J, Berntorp E, van den Berg M, Blanchette V, Donfield S, Gringeri A, Hilgartner M, Kulkarni R, Leissinger C, Negrier C, Nuss R, Petterson H, Petrini P, Poulios N, Schramm W. Unresolved issues in prophylaxis. Haemophilia. 2002 Nov; 8(6):817-21.
      View in: PubMed
    89. Aledort LM. Can costs of hemophilia products be curtailed? Not as we do business today! Thromb Haemost. 2002 Oct; 88(4):541.
      View in: PubMed
    90. Engels EA, Clark E, Aledort LM, Goedert JJ, Whitby D. Kaposi's sarcoma-associated herpesvirus infection in elderly Jews and non-Jews from New York City. Int J Epidemiol. 2002 Oct; 31(5):946-50.
      View in: PubMed
    91. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood. 2002 Sep 1; 100(5):1584-9.
      View in: PubMed
    92. Diamondstone LS, Aledort LM, Goedert JJ. Factors predictive of death among HIV-uninfected persons with haemophilia and other congenital coagulation disorders. Haemophilia. 2002 Sep; 8(5):660-7.
      View in: PubMed
    93. Brown SA, Aledort LM, Lee CA. Haemostasis: from bench to bedside. Haemophilia. 2002 Sep; 8(5):685-93.
      View in: PubMed
    94. Aledort LM. The role of porcine factor VIII in the management of unexpected bleeding episodes. Haemophilia. 2002 Jan; 8 Suppl 1:17-9; discussion 28-32.
      View in: PubMed
    95. Dave SP, Greenstein AJ, Sachar DB, Harpaz N, Aledort L. Bleeding diathesis in amyloidosis with renal insufficiency associated with Crohn's disease: response to desmopressin. Am J Gastroenterol. 2002 Jan; 97(1):187-9.
      View in: PubMed
    96. Tarantino M, Aledort L. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors. Transfusion. 2001 Dec; 41(12):1628-9.
      View in: PubMed
    97. Doti CA, Gondolesi GE, Sheiner PA, Emre S, Miller CM, Aledort LM. Leukemia after liver transplant. Transplantation. 2001 Nov 27; 72(10):1643-6.
      View in: PubMed
    98. Aledort LM. Hemophilia. N Engl J Med. 2001 Oct 4; 345(14):1066; author reply 1067.
      View in: PubMed
    99. Kulkarni R, Aledort LM, Berntorp E, Brackman HH, Brown D, Cohen AR, Ewing NP, Gringeri A, Gruppo R, Hoots K, Leissenger C, Peerlinck K, Poon MC, Wong WY. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol. 2001 Aug; 67(4):240-6.
      View in: PubMed
    100. Aledort LM. Adverse reactions related to rVIIa? Am J Hematol. 2001 Jul; 67(3):213.
      View in: PubMed
    101. White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001 Mar; 85(3):560.
      View in: PubMed
    102. Salkowitz JR, Purvis SF, Meyerson H, Zimmerman P, O'Brien TR, Aledort L, Eyster ME, Hilgartner M, Kessler C, Konkle BA, White GC, Goedert JJ, Lederman MM. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin Immunol. 2001 Feb; 98(2):200-11.
      View in: PubMed
    103. Aledort LM. Rebuttal to massive skin necrosis associated to the prothrombin gene G20210A mutation. Thromb Haemost. 2001 Feb; 85(2):374.
      View in: PubMed
    104. Aledort LM. Making a therapeutic choice: human versus recombinant fractions - can we do it? Haemophilia. 2001 Jan; 7 Suppl 1:1-3.
      View in: PubMed
    105. Aledort LM, Green D, Teitel JM. Unexpected bleeding disorders. Hematology Am Soc Hematol Educ Program. 2001; 306-21.
      View in: PubMed
    106. Aledort LM. Issues in making a therapeutic choice: recombinant and/or human-derived products. Haemophilia. 2001 Jan; 7(1):89-90.
      View in: PubMed
    107. Aledort LM. Economics of hemophilia care. Haemostasis. 2000 Nov-Dec; 30(6):333-6.
      View in: PubMed
    108. Aledort LM, Kroner B, Mariani G. Hemophilia treatment. Immune tolerance induction: treatment duration analysis and economic considerations. Haematologica. 2000 Oct; 85(10 Suppl):83-5.
      View in: PubMed
    109. Kadir RA, Aledort LM. Obstetrical and gynaecological bleeding: a common presenting symptom. Clin Lab Haematol. 2000 Oct; 22 Suppl 1:12-6; discussion 30-2.
      View in: PubMed
    110. Aledort LM. Unexpected bleeding disorders: identification, diagnosis and management. Haemophilia. 2000 Sep; 6(5):592-4.
      View in: PubMed
    111. Aledort LM. rFVIIa--its thrombogenicity. Thromb Haemost. 2000 Sep; 84(3):522-3.
      View in: PubMed
    112. Brown LK, Schultz JR, Parsons JT, Butler RB, Forsberg AD, Kocik SM, King G, Manco-Johnson M, Aledort L. Sexual behavior change among human immunodeficiency virus-infected adolescents with hemophilia. Adolescent Hemophilia Behavioral Intervention Evaluation Project Study Group. Pediatrics. 2000 Aug; 106(2):E22.
      View in: PubMed
    113. Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent? Thromb Haemost. 2000 May; 83(5):637-8.
      View in: PubMed
    114. Aledort LM. Factor VIII inhibitors. Immune tolerance induction: is it cost effective? We know too little. Semin Thromb Hemost. 2000; 26(2):189-93.
      View in: PubMed
    115. Pollmann H, Aledort L. Albumin-free formulated recombinant factor VIII preparations--how big a step forward? Thromb Haemost. 1999 Oct; 82(4):1370-1.
      View in: PubMed
    116. Aledort LM. Immune tolerance in hemophiliacs: can we afford it? Is it worth it? Baxter Previously Untreated Patient Study Group. Transfusion. 1999 Sep; 39(9):1034-5.
      View in: PubMed
    117. Nguyêñ GT, Carrington M, Beeler JA, Dean M, Aledort LM, Blatt PM, Cohen AR, DiMichele D, Eyster ME, Kessler CM, Konkle B, Leissinger C, Luban N, O'Brien SJ, Goedert JJ, O'Brien TR. Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr. 1999 Sep 1; 22(1):75-82.
      View in: PubMed
    118. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998 Dec; 80(6):912-8.
      View in: PubMed
    119. Aledort LM. Unsolved problems in haemophilia. Haemophilia. 1998 Jul; 4(4):341-5.
      View in: PubMed
    120. Bohn RL, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost. 1998 May; 79(5):932-7.
      View in: PubMed
    121. Kavakli K, Aledort LM. Circumcision and haemophilia: a perspective. Haemophilia. 1998 Jan; 4(1):1-3.
      View in: PubMed
    122. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1998 Jan; 4(1):68.
      View in: PubMed
    123. Aledort LM. von Willebrand disease: from the bedside to therapy. Thromb Haemost. 1997 Jul; 78(1):562-5.
      View in: PubMed
    124. Seremetis SV, Aledort LM. Desmopressin nasal spray for hemophilia A and type I von Willebrand disease. Ann Intern Med. 1997 May 1; 126(9):744-5.
      View in: PubMed
    125. Scaradavou A, Woo B, Woloski BM, Cunningham-Rundles S, Ettinger LJ, Aledort LM, Bussel JB. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood. 1997 Apr 15; 89(8):2689-700.
      View in: PubMed
    126. Ragni MV, Belle SH, Jaffe R, Locker J, Duerstein SL, Bass DC, Addiego JE, Aledort LM, Barron LE, Brettler DB, Buchanan GR, Gill JC, Ewenstein BM, Green D, Hilgartner MW, Hoots WK, Kisker CT, Lovrien EW, Rutherford CJ, Sanders NL, Smith KJ, Stabler SP, Swindells S, White GC, Kingsley LA. AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep; 13(1):78-86.
      View in: PubMed
    127. O'Brien TR, Blattner WA, Waters D, Eyster E, Hilgartner MW, Cohen AR, Luban N, Hatzakis A, Aledort LM, Rosenberg PS, Miley WJ, Kroner BL, Goedert JJ. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA. 1996 Jul 10; 276(2):105-10.
      View in: PubMed
    128. Gilbert MS, Aledort LM, Seremetis S, Needleman B, Oloumi G, Forster A. Long term evaluation of septic arthritis in hemophilic patients. Clin Orthop Relat Res. 1996 Jul; (328):54-9.
      View in: PubMed
    129. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, Blanchette VS, Bussel JB, Cines DB, Kelton JG, Lichtin AE, McMillan R, Okerbloom JA, Regan DH, Warrier I. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996 Jul 1; 88(1):3-40.
      View in: PubMed
    130. Aledort LM. Hemophilia: yesterday, today, and tomorrow. Mt Sinai J Med. 1996 May-Sep; 63(3-4):225-35.
      View in: PubMed
    131. Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it? Blood Coagul Fibrinolysis. 1996 Mar; 7 Suppl 1:S35-7.
      View in: PubMed
    132. Aledort LM. Inhibitors to coagulation: can we afford immune tolerance induction regimens? Vox Sang. 1996; 70 Suppl 1:77-8.
      View in: PubMed
    133. Aledort LM, Mohandas K. Transfusion requirements in patients with malignancy. Semin Hematol. 1996 Jan; 33(1 Suppl 1):6-9.
      View in: PubMed
    134. Kessler CM, Aledort LM. The economics of immune tolerance and treatment of hemophiliacs with inhibitors. Vox Sang. 1996; 70 Suppl 1:74-6.
      View in: PubMed
    135. Ehmann WC, Eyster ME, Aledort LM, Goedert JJ. Causes of death in haemophilia. Nature. 1995 Nov 9; 378(6553):124.
      View in: PubMed
    136. Aledort LM, Hoots WK, Wasserman J. Medical necessity--a threat to treatment of chronic disease. Transfusion. 1995 Aug; 35(8):712.
      View in: PubMed
    137. Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood. 1995 Jul 15; 86(2):797-804.
      View in: PubMed
    138. Lederman MM, Jackson JB, Kroner BL, White GC, Eyster ME, Aledort LM, Hilgartner MW, Kessler CM, Cohen AR, Kiger KP, et al. Human immunodeficiency virus (HIV) type 1 infection status and in vitro susceptibility to HIV infection among high-risk HIV-1-seronegative hemophiliacs. J Infect Dis. 1995 Jul; 172(1):228-31.
      View in: PubMed
    139. Aledort LM. Some aspects on the management of hemophilia. Thromb Haemost. 1995 Jul; 74(1):440-3.
      View in: PubMed
    140. O'Brien TR, Diamondstone L, Fried MW, Aledort LM, Eichinger S, Eyster ME, Hilgartner MW, White G, Di Bisceglie AM, Goedert JJ. Idiopathic CD4+ T-lymphocytopenia in HIV seronegative men with hemophilia and sex partners of HIV seropositive men. Multicenter Hemophilia Cohort Study. Am J Hematol. 1995 Jul; 49(3):201-6.
      View in: PubMed
    141. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion. 1995 May; 35(5):427-30.
      View in: PubMed
    142. Poon MC, Aledort LM, Anderle K, Kunschak M, Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion. 1995 Apr; 35(4):319-23.
      View in: PubMed
    143. Koblin BA, Aledort L, Hilgartner M, Lipton R, Goldberg I, Gaynor S, Feeley M, Forster A, Taylor PE, Stevens CE. A study of hepatitis A virus infection among hemophilia patients in New York City. Transfusion. 1995 Apr; 35(4):362-3.
      View in: PubMed
    144. Gaynor S, Aledort L, Hilgartner M, Lipton R, Saidi P, Strazzabosco J, Phatak P, Pratok P [corrected to Phatak P]. Haemophilia treatment centres: old and new challenges. Lancet. 1995 Mar 11; 345(8950):653.
      View in: PubMed
    145. Shapiro A, Abe T, Aledort LM, Anderle K, Hilgartner MW, Kunschak M, Preston FE, Rivard GE, Schimpf K. Low risk of viral infection after administration of vapor-heated factor VII concentrate or factor IX complex in first-time recipients of blood components. International Factor Safety Study Group. Transfusion. 1995 Mar; 35(3):204-8.
      View in: PubMed
    146. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. Int J Technol Assess Health Care. 1995; 11(2):327-44.
      View in: PubMed
    147. Cagnoni PJ, Aledort L. Gastrointestinal bleeding in hemophilia as a complication of the use of over the counter non-steroidal anti-inflammatory drugs. Am J Hematol. 1994 Dec; 47(4):336-7.
      View in: PubMed
    148. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol. 1994 Nov; 47(3):208-17.
      View in: PubMed
    149. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994 Oct; 236(4):391-9.
      View in: PubMed
    150. Goedert JJ, Cohen AR, Kessler CM, Eichinger S, Seremetis SV, Rabkin CS, Yellin FJ, Rosenberg PS, Aledort LM. Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Lancet. 1994 Sep 17; 344(8925):791-2.
      View in: PubMed
    151. Bray GL, Aledort LM. Considerations governing factor IX product choice in hemophilia B. Transfusion. 1994 Jun; 34(6):554-5.
      View in: PubMed
    152. Goedert JJ, Garvey L, Hilgartner MW, Blatt PM, Aledort LM, Cohen AR, Kessler CM, White GC, Mandalaki T, Cook RA, et al. Risk of HIV infection and AIDS in women and girls with coagulation disorders. AIDS. 1994 Apr; 8(4):564-5.
      View in: PubMed
    153. Mannucci PM, Brettler DB, Aledort LM, Lusher JM, Abildgaard CF, Schwartz RS, Hurst D. Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. Blood. 1994 Apr 1; 83(7):1958-62.
      View in: PubMed
    154. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr. 1994 Mar; 7(3):279-86.
      View in: PubMed
    155. Mosley JW, Nowicki MJ, Kasper CK, Donegan E, Aledort LM, Hilgartner MW, Operskalski EA. Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group. Vox Sang. 1994; 67 Suppl 1:24-8.
      View in: PubMed
    156. Aledort LM. Introduction: replacement therapy for hemophilia: impact on the immune system. Semin Hematol. 1993 Oct; 30(4 Suppl 5):1.
      View in: PubMed
    157. Seremetis SV, Aledort LM, Bergman GE, Bona R, Bray G, Brettler D, Eyster ME, Kessler C, Lau TS, Lusher J, et al. Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet. 1993 Sep 18; 342(8873):700-3.
      View in: PubMed
    158. Aledort LM. Consequences of chronic hepatitis C: a review article for the hematologist. Am J Hematol. 1993 Sep; 44(1):29-37.
      View in: PubMed
    159. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet. 1993 Aug 21; 342(8869):462-4.
      View in: PubMed
    160. Hassett J, Gjerset GF, Mosley JW, Fletcher MA, Donegan E, Parker JW, Counts RB, Aledort LM, Lee H, Pike MC. Effect on lymphocyte subsets of clotting factor therapy in human immunodeficiency virus-1-negative congenital clotting disorders. The Transfusion Safety Study Group. Blood. 1993 Aug 15; 82(4):1351-7.
      View in: PubMed
    161. Aledort LM. World registry on factor VIII inhibitor patients: why? Semin Hematol. 1993 Apr; 30(2 Suppl 1):7-9.
      View in: PubMed
    162. Seremetis SV, Aledort LM. Congenital bleeding disorders. Rational treatment options. Drugs. 1993 Apr; 45(4):541-7.
      View in: PubMed
    163. Ragni MV, Belle SH, Jaffe RA, Duerstein SL, Bass DC, McMillan CW, Lovrien EW, Aledort LM, Kisker CT, Stabler SP, et al. Acquired immunodeficiency syndrome-associated non-Hodgkin's lymphomas and other malignancies in patients with hemophilia. Blood. 1993 Apr 1; 81(7):1889-97.
      View in: PubMed
    164. Nowicki MJ, Mosley JW, Koerper MA, Aledort LM, Lusher JM, Hilgartner MW. Passive antibody to hepatitis A virus in US haemophiliacs. Lancet. 1993 Feb 27; 341(8844):562.
      View in: PubMed
    165. Aledort LM, Operskalski EA, Dietrich SL, Koerper MA, Gjerset GF, Lusher JM, Lian EC, Mosley JW. Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group. N Engl J Med. 1993 Feb 11; 328(6):441-2.
      View in: PubMed
    166. Eyster ME, Rabkin CS, Hilgartner MW, Aledort LM, Ragni MV, Sprandio J, White GC, Eichinger S, de Moerloose P, Andes WA, et al. Human immunodeficiency virus-related conditions in children and adults with hemophilia: rates, relationship to CD4 counts, and predictive value. Blood. 1993 Feb 1; 81(3):828-34.
      View in: PubMed
    167. Aledort LM. Prophylaxis: the next haemophilia treatment. J Intern Med. 1992 Jul; 232(1):1-2.
      View in: PubMed
    168. Rabkin CS, Hilgartner MW, Hedberg KW, Aledort LM, Hatzakis A, Eichinger S, Eyster ME, White GC, Kessler CM, Lederman MM, et al. Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA. 1992 Feb 26; 267(8):1090-4.
      View in: PubMed
    169. Mannucci PM, Schimpf K, Abe T, Aledort LM, Anderle K, Brettler DB, Hilgartner MW, Kernoff PB, Kunschak M, McMillan CW, et al. Low risk of viral infection after administration of vapor-heated factor VIII concentrate. International Investigator Group. Transfusion. 1992 Feb; 32(2):134-8.
      View in: PubMed
    170. Aledort LM, Hilgartner MW, Pike MC, Gjerset GF, Koerper MA, Lian EY, Lusher JM, Mosley JW. Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group. BMJ. 1992 Jan 25; 304(6821):212-6.
      View in: PubMed
    171. Aledort LM. Arthropathy and substitution therapy. Haemostasis. 1992; 22(5):245-6.
      View in: PubMed
    172. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med. 1991 Nov 15; 115(10):764-8.
      View in: PubMed
    173. Weissman D, Kornbluth AA, Gumaste VV, Waye JD, Dave PB, Aledort L. Colonoscopic polypectomy in patients with bleeding disorders. Endoscopy. 1991 Nov; 23(6):354-5.
      View in: PubMed
    174. Lusher JM, Operskalski EA, Aledort LM, Dietrich SL, Gjerset GF, Hilgartner MW, Koerper MA, Pegelow CH, Lee H, Mosley JW. Risk of human immunodeficiency virus type 1 infection among sexual and nonsexual household contacts of persons with congenital clotting disorders. Pediatrics. 1991 Aug; 88(2):242-9.
      View in: PubMed
    175. Aledort LM. Treatment of von Willebrand's disease. Mayo Clin Proc. 1991 Aug; 66(8):841-6.
      View in: PubMed
    176. Aledort LM. A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment. Semin Hematol. 1991 Jul; 28(3 Suppl 6):1-2.
      View in: PubMed
    177. Bussel JB, Graziano JN, Kimberly RP, Pahwa S, Aledort LM. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect. Blood. 1991 May 1; 77(9):1884-93.
      View in: PubMed
    178. Arkin S, Rose E, Forster A, Aledort LM. Clinical efficacy of recombinant factor VIII. The rFactor VIII Clinical Trial Group. Semin Hematol. 1991 Apr; 28(2 Suppl 1):47-51.
      View in: PubMed
    179. Rose EH, Aledort LM. Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease. Ann Intern Med. 1991 Apr 1; 114(7):563-8.
      View in: PubMed
    180. Uehlinger J, Button GR, McCarthy J, Forster A, Watt R, Aledort LM. Immunoadsorption for coagulation factor inhibitors. Transfusion. 1991 Mar-Apr; 31(3):265-9.
      View in: PubMed
    181. Schwartz RS, Abildgaard CF, Aledort LM, Arkin S, Bloom AL, Brackmann HH, Brettler DB, Fukui H, Hilgartner MW, Inwood MJ, et al. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. recombinant Factor VIII Study Group. N Engl J Med. 1990 Dec 27; 323(26):1800-5.
      View in: PubMed
    182. Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol. 1990 Oct; 76(2):238-41.
      View in: PubMed
    183. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion. 1990 Sep; 30(7):626-30.
      View in: PubMed
    184. Lipton RA, Aledort LM, Hilgartner M. The physician-directed blood product purchasing consortium during a worldwide shortage of factor VIII concentrate. Transfusion. 1990 Jul-Aug; 30(6):573.
      View in: PubMed
    185. Rose E, Forster A, Aledort LM. Correction of prolonged bleeding time in von Willebrand's disease with Humate-P. Transfusion. 1990 May; 30(4):381.
      View in: PubMed
    186. Dietrich SL, Mosley JW, Lusher JM, Hilgartner MW, Operskalski EA, Habel L, Aledort LM, Gjerset GF, Koerper MA, Lewis BH, et al. Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group. Vox Sang. 1990; 59(3):129-35.
      View in: PubMed
    187. Uehlinger J, Aledort LM. Blood-product usage in cardiac surgery. J Cardiothorac Anesth. 1989 Dec; 3(6):776-84.
      View in: PubMed
    188. Goedert JJ, Kessler CM, Aledort LM, Biggar RJ, Andes WA, White GC, Drummond JE, Vaidya K, Mann DL, Eyster ME, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med. 1989 Oct 26; 321(17):1141-8.
      View in: PubMed
    189. Driscoll MC, Bouhassira E, Aledort LM. A codon 338 nonsense mutation in the factor IX gene in unrelated hemophilia B patients: factor IX338 New York. Blood. 1989 Aug 1; 74(2):737-42.
      View in: PubMed
    190. Aledort LM, Essig B. AIDS laws--impractical solutions to practical problems. Hosp Pract (Off Ed). 1989 Jul 15; 24(7):11-3.
      View in: PubMed
    191. Antman KH, Aledort LM, Yarbro J, Wilensky G, Wojcik S, Monaco GP, Windham S. Cost-effectiveness and reimbursement in patient care. Semin Hematol. 1989 Jul; 26(3 Suppl 3):32-45.
      View in: PubMed
    192. Brettler DB, Forsberg AD, Levine PH, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med. 1989 Jun; 149(6):1381-5.
      View in: PubMed
    193. Aledort LM. New approaches to management of bleeding disorders. Hosp Pract (Off Ed). 1989 Feb 15; 24(2):207-11, 214, 219-21 passim.
      View in: PubMed
    194. Uehlinger J, Rose E, Aledort LM, Lemer R. Successful treatment of an acquired von Willebrand factor antibody by extracorporeal immunoadsorption. N Engl J Med. 1989 Jan 26; 320(4):254-5.
      View in: PubMed
    195. Lang DJ, Kovacs AA, Zaia JA, Doelkin G, Niland JC, Aledort L, Azen SP, Fletcher MA, Gauderman J, Gjerset GJ, et al. Seroepidemiologic studies of cytomegalovirus and Epstein-Barr virus infections in relation to human immunodeficiency virus type 1 infection in selected recipient populations. Transfusion Safety Study Group. J Acquir Immune Defic Syndr. 1989; 2(6):540-9.
      View in: PubMed
    196. Aledort LM, Hilgartner M, Lipton RA. Hemophilia--a treatment in crisis. N Engl J Med. 1988 Oct 13; 319(15):1017.
      View in: PubMed
    197. Driscoll MC, Dispenzieri A, Tobias E, Miller CH, Aledort LM. A second BamHI DNA polymorphism and haplotype association in the factor IX gene. Blood. 1988 Jul; 72(1):61-5.
      View in: PubMed
    198. Bussel JB, Pham LC, Aledort L, Nachman R. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood. 1988 Jul; 72(1):121-7.
      View in: PubMed
    199. Aledort LM. Cryoprecipitate revisited. Transfusion. 1988 Jul-Aug; 28(4):295-6.
      View in: PubMed
    200. Aledort LM, Lipton RA, Hilgartner M. A consortium for purchase of blood products directed by physicians. Ann Intern Med. 1988 May; 108(5):754-6.
      View in: PubMed
    201. Aledort LM. Blood products and immune changes: impacts without HIV infection. Semin Hematol. 1988 Apr; 25(2 Suppl 1):14-9.
      View in: PubMed
    202. Wallace EZ, Aledort LM, Levere R, Mushlin AI. A response to the recommendations of the New York State Commission on Graduate Medical Education concerning teaching in ambulatory care settings. N Y State J Med. 1987 Nov; 87(11):613-4.
      View in: PubMed
    203. Bianchi L, Desmet VJ, Popper H, Scheuer PJ, Aledort LM, Berk PD. Histologic patterns of liver disease in hemophiliacs, with special reference to morphologic characteristics of non-A, non-B hepatitis. Semin Liver Dis. 1987 Aug; 7(3):203-9.
      View in: PubMed
    204. Carnelli V, Gomperts ED, Friedman A, Aledort L, Hilgartner M, Dietrich S, Fedor EJ. Assessment for evidence of non A-non B hepatitis in patients given n-heptane-suspended heat-treated clotting factor concentrates. Thromb Res. 1987 Jun 15; 46(6):827-34.
      View in: PubMed
    205. Miller CH, Hilgartner MW, Aledort LM. Reproductive choices in hemophilic men and carriers. Am J Med Genet. 1987 Mar; 26(3):591-8.
      View in: PubMed
    206. Miller CH, Aledort LM. Discriminant analysis for probability of hemophilia A carriership. Blood. 1987 Feb; 69(2):704-5.
      View in: PubMed
    207. Aledort LM. Factor VIII/von Willebrand factor replacement therapy. Problems and challenges. Ann N Y Acad Sci. 1987; 509:49-52.
      View in: PubMed
    208. Fruchtman S, Aledort LM. Disseminated intravascular coagulation. J Am Coll Cardiol. 1986 Dec; 8(6 Suppl B):159B-167B.
      View in: PubMed
    209. Aledort LM. Much to know. Keio J Med. 1986 Oct; 35(4):291-7.
      View in: PubMed
    210. Driscoll MC, Miller CH, Goldberg JD, Aledort LM, Hoyer LW, Golbus MS. Recombination between factor VIII:C gene and St14 locus. Lancet. 1986 Aug 2; 2(8501):279.
      View in: PubMed
    211. Miller CH, Hilgartner MW, Harris MB, Bussel JB, Aledort LM. Concurrence of von Willebrand's disease and hemophilia A: implications for carrier detection and prevalence. Am J Med Genet. 1986 May; 24(1):83-94.
      View in: PubMed
    212. Markova I, Forbes CD, Aledort LM, Inwood M, Mandalaki T, Miller CH, Pittadaki J. A comparison of the availability and content of genetic counseling as perceived by hemophilic men and carriers in the U.S.A., Canada, Scotland, and Greece. Am J Med Genet. 1986 May; 24(1):7-21.
      View in: PubMed
    213. O'Grady JG, Langley PG, Isola LM, Aledort LM, Williams R. Coagulopathy of fulminant hepatic failure. Semin Liver Dis. 1986 May; 6(2):159-63.
      View in: PubMed
    214. Jason JM, McDougal JS, Dixon G, Lawrence DN, Kennedy MS, Hilgartner M, Aledort L, Evatt BL. HTLV-III/LAV antibody and immune status of household contacts and sexual partners of persons with hemophilia. JAMA. 1986 Jan 10; 255(2):212-5.
      View in: PubMed
    215. Eyster ME, Whitehurst DA, Catalano PM, McMillan CW, Goodnight SH, Kasper CK, Gill JC, Aledort LM, Hilgartner MW, Levine PH, et al. Long-term follow-up of hemophiliacs with lymphocytopenia or thrombocytopenia. Blood. 1985 Dec; 66(6):1317-20.
      View in: PubMed
    216. Aledort LM, Levine PH, Hilgartner M, Blatt P, Spero JA, Goldberg JD, Bianchi L, Desmet V, Scheuer P, Popper H, et al. A study of liver biopsies and liver disease among hemophiliacs. Blood. 1985 Aug; 66(2):367-72.
      View in: PubMed
    217. Johnson RE, Lawrence DN, Evatt BL, Bregman DJ, Zyla LD, Curran JW, Aledort LM, Eyster ME, Brownstein AP, Carman CJ. Acquired immunodeficiency syndrome among patients attending hemophilia treatment centers and mortality experience of hemophiliacs in the United States. Am J Epidemiol. 1985 Jun; 121(6):797-810.
      View in: PubMed
    218. Jason J, Hilgartner M, Holman RC, Dixon G, Spira TJ, Aledort L, Evatt B. Immune status of blood product recipients. JAMA. 1985 Feb 22; 253(8):1140-5.
      View in: PubMed
    219. Isola L, Forster A, Aledort LM. Desamino-D-arginine vasopressin and bleeding time in von Willebrand's disease. Ann Intern Med. 1984 Nov; 101(5):719-20.
      View in: PubMed
    220. Aledort LM. Alternatives to financing. Scand J Haematol Suppl. 1984; 40:455-7.
      View in: PubMed
    221. Aledort LM, Cohen M, Hilgartner M, Lipton R. Treatment of hemophiliacs with inhibitors: cost and effect on blood resources. Prog Clin Biol Res. 1984; 150:353-65.
      View in: PubMed
    222. Aledort LM. Side effects of substitution therapy. Scand J Haematol Suppl. 1984; 40:331-3.
      View in: PubMed
    223. Hilgartner MW, Aledort LM. AIDS in hemophilia. Ann N Y Acad Sci. 1984; 437:466-71.
      View in: PubMed
    224. Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood. 1983 Nov; 62(5):1135-8.
      View in: PubMed
    225. Aledort LM. AIDS: an update. Hosp Pract (Off Ed). 1983 Sep; 18(9):159-65, 169-71.
      View in: PubMed
    226. Radensky PW, Sorett E, Schoenbaum EE, Aledort LM. Ulcerative colitis and hemophilia A. Mt Sinai J Med. 1983 May-Jun; 50(3):268-9.
      View in: PubMed
    227. Aledort LM, Goodnight SH, Rao AV, Schwarz J, Whitehurst D, Shapiro SS. Impact of factor VIII deficiency on clotting factor utilization in the United States. Ric Clin Lab. 1983 Jan-Mar; 13(1):33-41.
      View in: PubMed
    228. Aledort LM, Pannekoek H, Vehar GA, Veltkamp JJ. What is the prospective impact of the recombinant DNA technique on the production of human plasma derivatives? Which are the derivates where donor plasma could be replaced? Vox Sang. 1983; 44(6):390-5.
      View in: PubMed
    229. Aledort LM. Current concepts in diagnosis and management of hemophilia. Hosp Pract (Off Ed). 1982 Oct; 17(10):77-84, 89-92.
      View in: PubMed
    230. Aledort LM. Coagulation and bleeding: the physiologic Janus. Hosp Pract (Off Ed). 1982 Sep; 17(9):13, 16.
      View in: PubMed
    231. Aledort LM. Lessons from hemophilia. N Engl J Med. 1982 Mar 11; 306(10):607-8.
      View in: PubMed
    232. Aledort LM. The availability of plasma products and the care of hemophilia patients. JAMA. 1981 Jul 10; 246(2):157.
      View in: PubMed
    233. Aledort LM, Goodnight SH. Hemophilia treatment: its relationship to blood products. Prog Hematol. 1981; 12:125-41.
      View in: PubMed
    234. Vlachakis ND, Aledort L. Hypertension and propranolol therapy: effect on blood pressure, plasma catecholamines and platelet aggregation. Am J Cardiol. 1980 Feb; 45(2):321-5.
      View in: PubMed
    235. Aledort LM. Problem of abnormal hemostasis in liver disease. Southeast Asian J Trop Med Public Health. 1979 Sep; 10(3):348-9.
      View in: PubMed
    236. Aledort LM. At last--a national blood policy? Hosp Pract. 1979 Jul; 14(7):11, 15.
      View in: PubMed
    237. Aledort LM. Comprehensive care of hemophilia. Southeast Asian J Trop Med Public Health. 1979 Jun; 10(2):280-1.
      View in: PubMed
    238. Vlachakis ND, Aledort L. Platelet aggregation in relationship to plasma catecholamines in patients with hypertension. Atherosclerosis. 1979 Apr; 32(4):451-60.
      View in: PubMed
    239. Vlachakis ND, Aledort L. Platelet lipid peroxides as determinant of platelet survival and sympathetic stimulation in patients with hypertension. Biochem Med. 1979 Feb; 21(1):94-103.
      View in: PubMed
    240. Evans BE, Irving SP, Aledort LM. Use of microcrystalline collagen for hemostasis after oral surgery in a hemophiliac. J Oral Surg. 1979 Feb; 37(2):126-8.
      View in: PubMed
    241. Evans BE, Aledort LM. Hemophilia and dental treatment. J Am Dent Assoc. 1978 May; 96(5):827-34.
      View in: PubMed
    242. Gendelman S, Aledort L, Hollin S. Intracranial meningioma in factor IX deficiency. JAMA. 1978 Feb 20; 239(8):748-9.
      View in: PubMed
    243. Evans BE, Aledort LM. Inhibition of ejaculation due to epsilon aminocaproic acid. N Engl J Med. 1978 Jan 19; 298(3):166-7.
      View in: PubMed
    244. Patel IP, Ambinder E, Holland JF, Aledort LM. In vitro and in vivo comparison of single-donor platelets and multiple-donor pooled platelets transfusions in leukemic patients. Transfusion. 1978 Jan-Feb; 18(1):116-9.
      View in: PubMed
    245. Aledort LM. Hematologic management and surgery in hemophilia. Mt Sinai J Med. 1977 May-Jun; 44(3):371-3.
      View in: PubMed
    246. Aledort LM. Methods of care, products available, complications of therapy. Mt Sinai J Med. 1977 May-Jun; 44(3):332-8.
      View in: PubMed
    247. Klein HG, Aledort LM, Bouma BN, Hoyer LW, Zimmerman TS, DeMets DL. A co-operative study for the detection of the carrier state of classic hemophilia. N Engl J Med. 1977 Apr 28; 296(17):959-62.
      View in: PubMed
    248. Evans BE, Aledort LM, Klatell J, Rubin M. Dental care for hemophiliacs. J Hosp Dent Pract. 1977 Apr-Jun; 11(2):10-2.
      View in: PubMed
    249. Aledort LM. World use of blood products for hemophilia. Scand J Haematol Suppl. 1977; 30:56-7.
      View in: PubMed
    250. Aledort LM. Factor IX and thrombosis. Scand J Haematol Suppl. 1977; 30:40-2.
      View in: PubMed
    251. Ambrose JA, Aledort LM. Human model for the study of abnormal platelet function in atherosclerotic heart disease. Am J Cardiol. 1976 Nov 4; 38(5):667-8.
      View in: PubMed
    252. Patel I, Aledort L, Puszkin EG. Amino acid metabolism of platelets in leukemia. Cancer Res. 1976 Apr; 36(4):1263-6.
      View in: PubMed
    253. Aledort LM. Platelets and thromboembolism. Semin Thromb Hemost. 1976 Jan; 2(3):136-45.
      View in: PubMed
    254. Aledort LM. Blood clotting abnormalities in liver disease. Prog Liver Dis. 1976; 5:350-62.
      View in: PubMed
    255. Aledort LM. Editorial: Animal research and the shrinking dollar. J Lab Clin Med. 1975 Dec; 86(6):899-900.
      View in: PubMed
    256. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975 Nov 15; 34(2):612.
      View in: PubMed
    257. Benis AM, Nossel HL, Aledort LM, Koffsky RM, Stevenson JF, Leonard EF, Shiang H, Litwak RS. Extracorporeal model for study of factors affecting thrombus formation. Thromb Diath Haemorrh. 1975 Sep 30; 34(1):127-44.
      View in: PubMed
    258. Tamari Y, Aledort L, Puszkin E, Degnan TJ, Wagner N, Kaplitt MJ, Peirce EC. Functional changes in platelets during extracorporeal circulation. Ann Thorac Surg. 1975 Jun; 19(6):639-47.
      View in: PubMed
    259. Walsh PN, Rizza CR, Evans BE, Aledort LM. The therapeutic role of epsilon-aminocaproic acid (EACA) for dental extractions in hemophiliacs. Ann N Y Acad Sci. 1975 Jan 20; 240:267-76.
      View in: PubMed
    260. Aledort LM. Letter: Blood fractions for haemophilia. Lancet. 1974 Dec 14; 2(7894):1452.
      View in: PubMed
    261. Puszkin S, Puszkin E, Katz AM, Aledort LM. Control of platelet actomyosin activity: effect of ADP on superprecipitation and ATPase activity of human platelet actomyosin. Biochim Biophys Acta. 1974 Apr 23; 347(1):102-12.
      View in: PubMed
    262. Berger S, Aledort LM, Gilbert HS, Hanson JP, Wasserman LR. Abnormalities of platelet function in patients with polycythemia vera. Cancer Res. 1973 Nov; 33(11):2683-7.
      View in: PubMed
    263. Hanson JP, Repke DI, Katz AM, Aledort LM. Calcium ion control of platelet thrombosthenin ATPase activity. Biochim Biophys Acta. 1973 Sep 26; 314(3):382-9.
      View in: PubMed
    264. Burrows L, Haimov M, Aledort L, Leiter E, Nirmul G, Shanzer H, Taub R, Glabman S. The platelet in the obliterate vascular rejection phenomenon. Transplant Proc. 1973 Mar; 5(1):157-60.
      View in: PubMed
    265. Aledort LM, Puszkin S, Puszkin E, Hanson J, Katz AM. Control of platelet contraction. Ser Haematol. 1973; 6(3):410-7.
      View in: PubMed
    266. Litwak RS, Jurado RA, Lukban SB, Mitchell BA, Kahn M, Berger S, Estioko MR, Aledort L. Perfusion without donor blood. J Thorac Cardiovasc Surg. 1972 Nov; 64(5):714-28.
      View in: PubMed
    267. Puszkin E, Gutfreund D, Aledort LM. Hemostatic abnormalities in heroin addicts. Transfusion. 1972 Jan-Feb; 12(1):9-11.
      View in: PubMed
    268. Aledort LM, Gilbert HS, Puszkin E. atterns of endogenous platelet serotonin release. Transfusion. 1971 Sep-Oct; 11(5):266-9.
      View in: PubMed
    269. Puszkin E, Puszkin S, Aledort LM. Colchicine-binding protein from human platelets and its effect on muscle myosin and platelet myosin-like thrombosthenin-M. J Biol Chem. 1971 Jan 25; 246(2):271-6.
      View in: PubMed
    270. Puszkin E, Aledort L, Puszkin S. The labeling of dicarboxylic amino acids and their amides by glucose and acetate in human platelets. J Lab Clin Med. 1970 Feb; 75(2):234-43.
      View in: PubMed
    271. Aledort LM, Hirsch C, Udkow M, Puszkin E. Effect of anticoagulants on calcium and magnesium content of human platelets. Transfusion. 1969 Jul-Aug; 9(4):212-3.
      View in: PubMed
    272. Puszkin E, Aledort L, Puszkin S. Human platelets: amino acid synthesis. Proc Soc Exp Biol Med. 1969 Jul; 131(3):957-9.
      View in: PubMed
    273. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968 Sep; 47(9):2169-80.
      View in: PubMed
    274. Aledort LM, Niemetz J. Dissociation of platelet aggregation from clot retraction, potassium loss, and adenosine triphosphatase activity. Proc Soc Exp Biol Med. 1968 Jul; 128(3):658-61.
      View in: PubMed
    275. Aledort LM, Troup SB, Weed RI. Inhibition of sulfhydryl-dependent platelet functions by penetrating and non-penetrating analogues of parachloromercuribenzene. Blood. 1968 Apr; 31(4):471-9.
      View in: PubMed
    276. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet. 1967 Sep 2; 2(7514):495-7.
      View in: PubMed
    277. Aledort LM, Lord GP. Idiopathic pulmonary hemosiderosis. Severe anemia without hemoptysis--one year follow-up of pulmonary function. Arch Intern Med. 1967 Aug; 120(2):220-3.
      View in: PubMed
    278. Aledort LM, Weed RI, Troup SB. Ionic effects on firefly bioluminescence assay of red blood cell ATP. Anal Biochem. 1966 Nov; 17(2):268-77.
      View in: PubMed
    279. Aledort LM, Hodges M, Brown JA. Irreversible renal failure due to malignant lymphoma. Ann Intern Med. 1966 Jul; 65(1):117-21.
      View in: PubMed
    280. Moss AJ, Aledort LM. Use of edrophonium (tensilon) in the evaluation of supraventricular tachycardias. Am J Cardiol. 1966 Jan; 17(1):58-62.
      View in: PubMed
    281. SHULMAN NR, MARDER VJ, ALEDORT LM, HILLER MC. ISOANTIBODIES AGAINST PLATELETS AND LEUKOCYTES. Bibl Haematol. 1964; 19:439-47.
      View in: PubMed
    282. SHULMAN NR, MARDER VJ, ALEDORT LM, HILLER MC. Complement-fixing isoantibodies against antigens common to platelets and leukocytes. Trans Assoc Am Physicians. 1962; 75:89-98.
      View in: PubMed
    283. MILLICHAP JG, MADSEN JA, ALEDORT LM. Studies in febrile seizures. V. Clinical and electroencephalographic study in unselected patients. Neurology. 1960 Jul; 10:643-53.
      View in: PubMed
    284. MILLICHAP JG, ALEDORT LM, MADSEN JA. A critical evaluation of therapy of febrile seizures. J Pediatr. 1960 Mar; 56:364-8.
      View in: PubMed
    Aledort's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067